IL31 and Alzheimer disease: Nemolizumab is an anti-IL-31Rα that is near commercialization for moderate-to-severe AD, Vixarelimab is an anti-OSMRβ that targets IL-31 and oncostatin-M (OSM) is currently in a Phase II study for prurigo nodularis.